BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have received a consensus rating of “Moderate Buy” from the eighteen analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $133.1333.

A number of equities research analysts have recently weighed in on BNTX shares. Morgan Stanley boosted their price objective on shares of BioNTech from $125.00 to $126.00 and gave the company an “overweight” rating in a report on Friday, April 10th. Raymond James Financial reissued an “outperform” rating on shares of BioNTech in a report on Tuesday, March 10th. Truist Financial raised shares of BioNTech to a “strong-buy” rating in a report on Wednesday, March 25th. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Finally, Berenberg Bank reiterated a “buy” rating on shares of BioNTech in a research report on Monday, April 13th.

BioNTech Trading Up 0.8%

Shares of NASDAQ BNTX opened at $102.92 on Friday. The firm has a market cap of $26.03 billion, a PE ratio of -19.64 and a beta of 1.58. BioNTech has a twelve month low of $79.52 and a twelve month high of $124.00. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $98.04 and a two-hundred day simple moving average of $101.07.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. BioNTech had a negative return on equity of 4.76% and a negative net margin of 38.09%.The business had revenue of $1.06 billion during the quarter. Analysts expect that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Large investors have recently bought and sold shares of the business. Larson Financial Group LLC grew its stake in BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares in the last quarter. EFG International AG acquired a new stake in shares of BioNTech during the 4th quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of BioNTech by 520.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after buying an additional 260 shares during the last quarter. Financial Consulate Inc. purchased a new position in shares of BioNTech during the 3rd quarter worth approximately $36,000. Finally, Huntington National Bank boosted its position in shares of BioNTech by 1,266.7% during the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after purchasing an additional 380 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.